Parsaclisib Improved Myelofibrosis Symptoms in Patients With Suboptimal Response to Ruxolitinib
At 12 weeks, most patients had a reduction in spleen volume.
At 12 weeks, most patients had a reduction in spleen volume.
Researchers sought to determine whether LCL161 would induce a response in patients with myelofibrosis.
Using validated tools, investigators determined that patients with a MPN were likely to experience significant symptoms of depression.
Previously conducted retrospective studies may have underestimated the incidence of hydroxyurea-related skin toxicity in patients with MPNs.
Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.
Fedratinib, a selective inhibitor of JAK2, was approved in 2019 by the US FDA for the treatment of certain groups of patients with myelofibrosis.
Identification of the underlying pattern for ruxolitinib failure in patients with myelofibrosis is a significant factor in determining appropriate treatment.
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
By week 24 of the study, a reduction in palpable spleen length of at least 50% was reported in more than half of patients who underwent splenomegaly.
Researchers assessed how the reasons that led to discontinuation of ruxolitinib influenced survival in patients with myelofibrosis.